Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

• Published in: Nature communications Vol. 8; no. 1; pp. 1785 - 12
• Main Authors: Gu, Yanyun, Wang, Xiaokai, Li, Junhua, Zhang, Yifei, Zhong, Huanzi, Liu, Ruixin, Zhang, Dongya, Feng, Qiang, Xie, Xiaoyan, Hong, Jie, Ren, Huahui, Liu, Wei, Ma, Jing, Su, Qing, Zhang, Hongmei, Yang, Jialin, Wang, Xiaoling, Zhao, Xinjie, Gu, Weiqiong, Bi, Yufang, Peng, Yongde, Xu, Xiaoqiang, Xia, Huihua, Li, Fang, Xu, Xun, Yang, Huanming, Xu, Guowang, Madsen, Lise, Kristiansen, Karsten, Ning, Guang, Wang, Weiqing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.11.2017; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326/2565/2134; 631/326/2565/2142; 631/443/319/1642/137; 692/308/575; Abundance; Acarbose; Antidiabetics; Bacteroides; Bile; Bile acids; Diabetes mellitus; Humanities and Social Sciences; Intestinal microflora; Metabolism; Microbiota; Microorganisms; multidisciplinary; Patients; Plasma levels; Relative abundance; Science; Science (multidisciplinary)

Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unc...